Correction: Imaging in staging, treatment planning, and monitoring of hepatocellular carcinoma for local and locoregional therapies: consensus recommendations from EORTC and ESGAR
Osman Öcal(Heidelberg University), Lukas Luerken, Christian Stroszczynski(University Hospital Carl Gustav Carus), Irene Bargellini(Candiolo Cancer Institute), Kerstin Schütte(Amsterdam University Medical Centers), Felix M. Mottaghy(College Board), Hossein Hemmatazad(University Hospital of Bern), Carolina de la Pinta(Instituto Cajal), Serena Pisoni(University Hospital of Bern), Daniela E. Oprea‐Lager(Amsterdam University Medical Centers), Christophe M. Deroose(KU Leuven), Ingo Einspieler(University Hospital Regensburg), Roberto Iezzi(Università Cattolica del Sacro Cuore), John Ramage(Hampshire Hospitals NHS Foundation Trust), Christoph J. Zech(University of Basel), Stefano Cappio(University Hospital Regensburg), Serdar Aslan(Ospedale San Giovanni Bellinzona), Bernhard Gebauer(Charité - Universitätsmedizin Berlin), Marino Venerito(John Radcliffe Hospital), Maxime Dewulf(Maastricht University), Lorenza Rimassa(Humanitas University), Cesare Guida(Maastricht University), Uli Fehrenbach(Charité - Universitätsmedizin Berlin), Timm Denecke(Leipzig University), Wolfgang G. Kunz(LMU Klinikum), Maria Antonietta Bali(Royal Marsden NHS Foundation Trust), Valeria Dionisi(Hampshire Hospitals NHS Foundation Trust), Arndt Vogel(Princess Margaret Cancer Centre), Huw Roach(Giresun University), Bruno Sangro(Clinica Universidad de Navarra), Nikolaos Kartalis(Karolinska University Hospital), Joost J.C. Verhoeff(University Medical Center Utrecht), Max Seidensticker(LMU Klinikum), Bora Peynırcıoğlu(Hacettepe University), Francesca De Felice(Policlinico Umberto I), Henning Wege(Universität Hamburg), Mark C. Burgmans(Leiden University Medical Center), David Pasquier(Centre National de la Recherche Scientifique), Roberto Cannella(University of Palermo)
Cited by 0
Related Papers
Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade
|Journal of Clinical Oncology|2014|2.8k
Hepatocellular carcinoma
|Nature Reviews Disease Primers|2016|2.7k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
|Science|2018|2.1k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k